Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL16239835 | 0.96 | SCN9A (0.49) | SCN9ASCN5AMAOBMAOARXRA | |
| SCHEMBL363861 | 0.87 | RXRA (0.49) | SCN9ASCN5ARXRARXRB | |
| SCHEMBL366513 | 0.85 | PTGER4 (0.47) | SCN9ASCN5ARXRARXRB | |
| Diethylamine SCHEMBL16240278 | 0.83 | RXRA (0.45) | SCN9ASCN5ARXRARXRB | |
| Diethylamine SCHEMBL16239544 | 0.81 | ADRB1 (0.44) | SCN9ASCN5ARXRARXRB | |
| SCHEMBL364950 | 0.81 | MAOB (0.66) | SCN9ASCN5AMAOBMAOA | |
| SCHEMBL364340 | 0.80 | RXRA (0.62) | SCN9ARXRARXRB | |
| SCHEMBL365348 | 0.78 | SCN9A (0.56) | SCN9ASCN5AMAOBMAOA | |
| Diethylamine SCHEMBL16239678 | 0.76 | RXRA (0.57) | SCN9ARXRARXRB | |
| SCHEMBL16240191 | 0.75 | SCN9A (0.76) | SCN9ASCN5AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-2593428-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109701-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 16/4885SCN5A 5/4885MAOB 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.